Mighty Therapeutics Overview
- Year Founded
-
2005
- Status
-
Private
- Employees
-
67
- Latest Deal Type
-
PE Growth
- Financing Rounds
-
11
Mighty Therapeutics General Information
Description
Developer of novel therapeutic compounds designed for the treatment of mitochondrial dysfunctions. The company offers injectable cardiolipin binders and small molecules for Barth syndrome and dry age-related macular degeneration, enabling patients to improve muscle strength and slow disease progression through therapies that address underlying mitochondrial dysfunction.
Contact Information
Website
www.mightytx.comCorporate Office
- 123 Highland Avenue
- Suite 201
- Needham, MA 02494
- United States
Corporate Office
- 123 Highland Avenue
- Suite 201
- Needham, MA 02494
- United States
Mighty Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Mighty Therapeutics Comparisons
Industry
Financing
Details
Mighty Therapeutics Competitors (49)
One of Mighty Therapeutics’s 49 competitors is AnTolRx, a Formerly VC-backed company based in Cambridge, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| AnTolRx | Formerly VC-backed | Cambridge, MA | ||||
| Cognition Therapeutics | Formerly VC-backed | New York, NY | ||||
| Enterome | Venture Capital-Backed | Paris, France | ||||
| Abliva | Formerly VC-backed | Lund, Sweden | ||||
| Rein Therapeutics | Formerly VC-backed | Austin, TX |
Mighty Therapeutics Patents
Mighty Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20260345720-A1 | Compositions, drug products, methods, and related uses for addressing dry age-related macular degeneration | Pending | 25-Apr-2025 | ||
| WO-2026227068-A1 | Compositions, drug products, methods, and related uses for addressing dry age-related macular degeneration | Pending | 25-Apr-2025 | ||
| WO-2026155975-A1 | Mitochondria-targeting cyclic peptides | Pending | 14-Jan-2025 | ||
| WO-2026151846-A1 | Compositions for use in the treatment of heart failure, idiopathic cardiomyopathy, dilated cardiomyopathy, restrictive cardiomyopathy, hypertrophic cardiomyopathy, or hypertensive cardiomyopathy | Pending | 09-Jan-2025 | ||
| WO-2026151834-A1 | Compounds for use in medical management of subjects with muscular dystrophy | Pending | 09-Jan-2025 | A61K38/07 |
Mighty Therapeutics Signals
Mighty Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Mighty Therapeutics FAQs
-
When was Mighty Therapeutics founded?
Mighty Therapeutics was founded in 2005.
-
Where is Mighty Therapeutics headquartered?
Mighty Therapeutics is headquartered in Needham, MA.
-
What is the size of Mighty Therapeutics?
Mighty Therapeutics has 67 total employees.
-
What industry is Mighty Therapeutics in?
Mighty Therapeutics’s primary industry is Drug Discovery.
-
Is Mighty Therapeutics a private or public company?
Mighty Therapeutics is a Private company.
-
What is Mighty Therapeutics’s current revenue?
The current revenue for Mighty Therapeutics is .
-
How much funding has Mighty Therapeutics raised over time?
Mighty Therapeutics has raised $150M.
-
Who are Mighty Therapeutics’s investors?
Morningside Group and Cornell University have invested in Mighty Therapeutics.
-
Who are Mighty Therapeutics’s competitors?
AnTolRx, Cognition Therapeutics, Enterome, Abliva, and Rein Therapeutics are some of the 49 competitors of Mighty Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process